[Evaluation of brain tumors using positron emission tomography]

Abstract

The clinical application of positron emission tomography (PET) for the evaluation of brain tumours has proved clinically valuable. Amino acid and FDG-glucose PET provide information on the degree of malignancy and the prognosis during the initial evaluation. After therapy, the residual tumour can be visualized and recurrence can be differentiated from necrosis. Amino acids have advantages over FDG for these clinical applications. Blood flow, oxygen extraction and metabolism and blood-brain barrier permeability are of minor relevance in clinical situations. Comparison of PET with MRI and MRS will provide new data. The quantitative information of the unique information yielded by PET will lead to a more important clinical role, as will the extrapolation of this experience to the SPECT technique.